Capabilities by Region: United Kingdom
Greenhill has considerable advisory experience in the United Kingdom. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout the United Kingdom.
Greenhill established its presence in the United Kingdom in January 1998 with the opening of a London office.
For more information on Greenhill’s advisory practice in the United Kingdom and our capabilities in the region, please contact President David Wyles or Head of U.K. M&A Dean Rodrigues in our London Office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
GWA Group Limited’s Door and Access Controls Business
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
Frutarom
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Cityfibre Infrastructure Holdings plc
Advised Antin Infrastructure Partners and West Street Infrastructure Partners, part of Goldman Sachs’ Merchant Banking division, in connection with the take private of CityFibre Infrastructure Holdings plc, a leading independent provider of wholesale fibre network infrastructure
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture